Epoprostenol Injection Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 1.5 mg/via;
Reference Brands: Flolan®(Us & Eu)
Category:
Orphan Drugs
Epoprostenol infusion solution is a prostacyclin analogue that dilates pulmonary blood vessels, reducing blood pressure in PAH. It inhibits platelet aggregation, preventing blood clots. Benefits include improved exercise capacity, symptom relief, and enhanced quality of life in PAH patients, especially those with advanced disease.
Epoprostenol injection is available in Injection
and strengths such as 1.5 mg/via;.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Epoprostenol injection is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Epoprostenol injection can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Epoprostenol infusion solution, marketed as Flolan® in the US and EU, is approved for pulmonary arterial hypertension. Regulatory dossiers include extensive clinical data, manufacturing details, and safety profiles submitted to FDA and EMA, supporting its approval for continued use. The solution is administered via continuous IV infusion, with dosing tailored individually. These dossiers ensure high-quality standards and efficacy. For in-depth insights into regulatory submissions, dossier requirements, and market approvals, visit PharmaTradz, your trusted source for pharmaceutical regulatory updates and industry insights.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing